Introduction
Dolastatin 10 (D10) is small peptide inhibiting microtubule assembly and tubulin polymerization that was isolated in 1987 from an Indian Ocean mollusc, the sea hare (Dolabella auricularia).
1 Although D10 displayed significant antitumor activity in preclinical models and demonstrated good tolerability in clinical settings, recent phase II clinical trials suggested that D10, as a single agent, lacked significant activity. [2] [3] [4] [5] TZT-1027 is a synthesized derivative of D10 with superior preclinical activity. 6 TZT-1027 showed notable antitumor activity against a broad range of human malignancies in vivo, including those resistant to conventional chemotherapeutic agents. 7 Superior antivascular activity resulting in the collapse of the tumor vasculature was demonstrated, compared with the activities of taxanes and Vinca alkaloids. [8] [9] [10] The first clinical phase I study of TZT-1027 was initiated in 1994, and another four studies have since been completed; a phase II study is currently ongoing. [11] [12] [13] The major toxicity was hematological, in the form of neutropenia and leukopenia. Reversible peripheral neurotoxic syndrome, alopecia, fatigue and anorexia were the principal nonhematological toxicities.
TZT-1027 is a mitotic spindle poison that interacts with tubulin at the Vinca alkaloids binding site, 14 but the spectra of antitumor activity of TZT-1027 and the Vinca alkaloids are different in vivo. 7, 10, 15 TZT-1027 also showed potent antitumor activity against a vincristine-resistant cell line. 7 A recent investigation of the mode of action reported that TZT-1027-induced apoptosis and cell arrest in the G 2 /M phase that was independent of caspase-3 or bcl-2. 16 According to in vitro studies performed with tumor tissue obtained from patients with lung and renal cell cancers, the activity of TZT-1027 is influenced less by the p53 mutation status than by DNA-damaging agents. 17 Despite these investigations, the mode of action and therapeutic class of TZT-1027 as an antimicrotubule agent remains unclear. To characterize the mode of action of this compound, microarray-based transcriptional profiles have been performed. 18, 19 Cell-based high-throughput screening technologies provide information about cellular pathways that control drug sensitivity. 20, 21 Drug-to-drug comparative approaches using microarray analyses are useful for identifying drug targets; the cellular effects caused by a novel drug of incompletely characterized specificity can be matched to 'reference profiles' of the cellular effects elicited by the specific inhibition of candidate analog-sensitive drugs. 22, 23 Thus, it has been proposed that phenotypic information generated by drug-induced alterations in gene expression can be matched to discrete interactions between the compound and the relevant protein targets. Using the drug-to-drug comparative approach of the microarray analysis, we obtained reference profiles of genomic expression data from cellular responses in a lung cancer cell line to antimicrotubule drugs, including five conventional agents and the mother compound D10. In the present study, we aimed to characterize TZT-1027 using these reference profiles.
Results

Growth inhibition
The growth inhibitory effect of TZT-1027 and the other six antimicrotubule agents was determined using an MTT assay. The PC-14 cell line was exposed to each drug for 72 h. The 50% growth inhibitory concentrations (IC 50 values) were as follows: TZT-1027, 0.02 nM; D10, 0.1 nM; VDS, 4 nM; VBL, 2 nM; VCR, 7 nM; TXL, 3 nM and TXT, 3 nM. Based on these results, TZT-1027 was over a hundred times more cytotoxic than the other taxanes and Vinca alkaloids.
Microarray data mining
The expression intensity of the array was normalized using a global normalization method. The change in gene expression was calculated as the intensity ratio between treated and untreated samples. The complete cDNA microarray data can be found in the Supplementary Tables. This supporting information contains the raw data, normalized data and a summary of the selected genes.
Common genes regulated by all antimicrotubule agents Of the 588 genes that were surveyed in the microarray analysis, 118 genes were upregulated by all seven antimicrotubules Drug characterization using molecular reference profiles Focusing on the 'reference profiles' of the drug-induced genomic response, we compared the profiles of TZT-1027 with those of five conventional antimicrotubule agents and the mother compound, D10. A principle component representation of the whole gene set in three-dimensional space clearly showed the relationship between TZT-1027 and the other six reference profiles ( Figure 1 ). All the drugs were separated according to each drug class in this profile. In comparison with these reference profiles, TZT-1027's profile was similar to that of D10 but different from those of the taxanes and Vinca alkaloids.
To investigate the differences in genomic response between the drug classes, we selected discriminatory genes that were regulated differently between the drug classes, compared with the complete gene set. Table 2 shows the genes whose expression profiles differed after exposure to dolastatins (TZT-1027 and D10) and the other antimicrotubule agents. The most discriminatory gene in this gene set was the drug-resistant gene, GSTO1. Using this gene set, the classes of antimicrotubule agents could be clearly separated (Figure 2a ). Discriminatory gene sets for the taxanes and Vinca alkaloids were obtained in a similar manner (Tables 3  and 4 ). The profiles of the discriminatory gene sets for the taxanes and Vinca alkaloids are shown in Figure 2b and c.
To further characterize TZT-1027, the genes that were regulated differently after exposure to TZT-1027 and D10 were investigated. Six genes that were regulated differently by a factor of more than one in a log ratio after exposure to each agent were selected (Table 5 ). Four cytoskeletal genes were included in this group. A three-dimensional representation using these six genes demonstrated that the profiles 
Validation of discriminatory genes by RT-PCR
The identified discriminatory genes GSTO1 and TIMP3 were validated using real-time RT-PCR ( Figure 4 ). To investigate whether the genomic responses of these genes depended on the cytotoxicity levels, the RT-PCR experiment was performed at different cytotoxicity levels (IC 90 and IC 10 ) of TZT-1027. The results are summarized in Figure 5 . These findings suggested that the selected genomic responses might not depend on the cytotoxicity levels, whereas the genomic response of GSTO1 demonstrated a dose dependency.
Discussion
In the present study, we characterized the novel antimicrotubule agent TZT-1027 using a microarray analysis. Dolastatins belong to a class of microtubule-destabilizing agents, but this classification is not sufficient for clinical use. Despite similarities in their mechanism of action and structure, antimicrotubule agents differ in their antitumor and toxicologic profiles. 24 It now seems that the most important action of antimicrotubule agents is not the regulation of microtubule-polymer mass (polymerization and depolymerization), but the suppression of spindlemicrotubule dynamics. 25 Furthermore, many of the drugs act not only on microtubules, but also on soluble tubulin, and the location of the specific binding site in tubulin and microtubules greatly affects the response of the microtubule system to the drug. 25 Therefore, to characterize the novel antimicrotubule agent TZT-1027, we analyzed drug-induced changes in gene expression using the microarray technique and compared the molecular profiles with those induced by the mother compound, D10, and other well-known antimicrotubule agents, such as Vinca alkaloids and taxanes.
For the profiles, we evaluated the IC 50 value of each drug using a growth inhibitory assay. We aimed to categorize the drugs based on their mechanisms of action; therefore, the changes in gene expression were, of necessity, induced at the same cytotoxicity level. The resulting expression profiles were obtained using a microarray containing B600 key genes applicable to antimicrotubule drug research, including genes involved with microtubule dynamics, cell-cycle regulation, angiogenesis and the extracellular matrix as well as cell adhesion receptors, oncogenes and tumor-suppressor genes. We focused on changes in gene expression because gene regulation should be correlated with the protein status modulated by the drugs. Figure 2 Spatial class separation of antimicrotubule agents using specific discriminatory genes. The axes represent the first three linear discriminants of the expression levels of (a) 11 dolastatin-discriminatory genes from Table 2 , (b) 9 taxane-discriminatory genes from Table 3 and (c) 5 Vinca alkaloid-discriminatory genes from Table 4 . TZT, TZT-1027; dolastatin 10, D10; VDS, vindesine; VCR, vincristine; VBL, vinblastine; TXL, paclitaxel; TXT, docetaxel. Of the 588 genes that were surveyed, about half of all the genes were regulated similarly by the seven drugs. The probability of these similar expression profiles occurring by chance is almost zero (Po1 Â 10
À100
). Furthermore, the functions of the clustered genes were associated with microtubule dynamics. The 118 genes that were upregulated were significantly associated with cell-cycle regulation, mitosis or apoptosis, whereas the 141 genes that were Abbreviations: GB, genebank accession number; TZT, TZT-1027; D10, dolastatin 10; VDS, vindesine; VBL, vinblastine; VCR, vincristine; TXL, paclitaxel; TXT, docetaxel.
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T Shimoyama et al downregulated were associated with cell communication and morphogenesis. Therefore, we concluded that the genomic response profiles represented the drug activities in PC-14 cells and investigated the discriminatory genes within each drug class to enable their further characterization. By comparing the resulting gene profiles, each drug was categorized according to its drug class based on its effects on microtubule modulation (Figure 1 ). This finding suggested that genomic response was mostly affected by the drugbinding site on the microtubules. TXT shares the same tubulin-binding site as TXL, and this site is distinct from the Vinca alkaloids binding site. 25 Although TXL has a 1.9-fold higher affinity for the binding site and polymerizes tubulin at 2.1-fold lower concentrations than TXL, 26 TXL and TXT induced similar gene expression profiles, compared with those induced by the other antimicrotubule drugs. Among the three Vinca alkaloids (VBL, VDS and VCR), the expression profile of VDS differed from those of the other two ( Figure 6 ). Natsume et al.
14 reported that all three Vinca alkaloids inhibited the polymerization of microtubules at a similar affinity. VBL and VCR are structurally very similar, whereas the structure of VDS differs from those of the other two. 27 This structural difference may be responsible for the different genomic responses. Vinca alkaloids and dolastatins are known to bind at so-called Vinca-binding domains in tubulin. 25 They share the same binding site and have similar affinities, 14, 28 whereas additional binding sites have either high affinities (Kd: 1-2 mmol) or low affinities (Kd: 0.25-3 mmol). 24 Previous studies have also reported that dolastatins can also bind at different sites from those used by Vinca alkaloids 14, 29 These additional binding sites might be responsible for the differences in genomic response induced by the dolastatins and Vinca alkaloids.
Interestingly, of the 31 discriminatory genes that were selected, six of them were intermediate filament (IF) genes like desmin, vimentin, desmocollin and keratin (Tables 2, 4,  5 ). In addition, four collagen genes and one Rho-regulator gene were also selected. These genes are all associated with cytoskeletal regulation by the Rho signaling pathway via 
T Shimoyama et al microtubule dynamics. 30 Rho proteins also modulate the extracellular matrix either by regulating the levels of MMPs (matrix metalloproteinase) or their antagonists, TIMPs (tissue inhibitor of metalloproteinase). 31 These results suggested that the difference in the tubulin-drug binding site might regulate the difference in the signal transduction.
Of the genes that discriminated between dolastatins and the other drug class, the most significant genes were GSTO1 and TIMP3. GSTO1 (glutathione transferase omega 1) is a member of the glutathione S-transferase (GST) family of phase II enzymes that catalyze glutathione-dependent detoxification. 32 The role of GST has been evaluated in drug resistance. Schisselbauer et al. 33 reported that an elevated GST level in tumors was detected after the development of clinical drug resistance. Ban et al. 34 reported that adriamycin, cisplatin and etoposide increased tumor sensitivity by inhibiting GST expression in a colon cancer cell line, but TXL and VCR did not alter sensitivity. TIMP3 is a protein that binds to the extracellular matrix 35 and belongs to a family of endogenous MMP inhibitors. Members of the MMP family play important roles in angiogenesis. 36 Therefore, TIMP3 is regarded as a potent inhibitor of angiogenesis and tumor growth. 37 Qi et al. 38 reported that TIMP3 blocks the binding of VEGF (vascular endothelial growth factor) to the VEGF receptor-2, inhibiting downstream signaling and angiogenesis. TZT-1027 showed antitumor activity in vivo against a hypervascular advanced-stage tumor from a VEGFtransfectant lung cancer cell line, whereas VCR and TXT did not. 10 The upregulation of TIMP3 by TZT-1027 is one possible mechanism for the superior antivascular activity of this drug, compared to that of taxanes and Vinca alkaloids.
To analyze whether similar genomic responses occurred in lung cancer cell lines other than PC-14, RT-PCR for GSTO1 and TIMP3 was performed in another lung cancer cell line, SBC-3, treated with TZT-1027 at IC 50 . GSTO1 and TIMP3 were downregulated in SBC-3 cells treated with dolastatins and upregulated in the cells treated with the other antimicrotubule agents, opposite to the profile seen for PC-14 cells (data not shown). This result suggested that these genes may have different genomic responses in other lung cancer cells.
This was a 'proof-of-principle study'. We demonstrated the various cellular responses to antimicrotubule agents at a gene expression level, even though the agents targeted the same molecules. We believe that this approach to characterizing drugs in vitro may be useful in clinical settings in that surrogate tissue, like peripheral blood mononuclear cells, can be used. The present findings obtained using our microarray analysis could greatly help us to understand the mode of action of TZT-1027 and other antimicrotubule agents. This capacity to identify therapeutic efficacy on the basis of gene expression signatures in vitro may be useful for drug discovery and drug target validation.
Materials and methods
Cell lines and cultures
A human non-small-cell-lung cancer cell line, PC-14, was provided by Professor Y Hayata, Tokyo Medical College. PC-14 was grown in RPMI-1640 medium (Nikken BioMedical Laboratory, Kyoto, Japan) supplemented with 10% fetal bovine serum, penicillin G and 100 mg/ml streptomycin solution and was maintained in a humidified 5% CO 2 atmosphere at 371C.
Drugs and culture
TZT-1027 and D10 were provided by Teikoku Hormone Mfg. Co. Ltd (Kawasaki, Japan) and were dissolved in and diluted with 0.05 M lactate buffer (pH 4.5). Vindesine (VDS), vincristine (VCR), vinblastine (VBL), docetaxel (TXT) and paclitaxel (TXL) were obtained from Shionogi Co. (Osaka, Japan), Shionogi Pharmaceutical Co. (Osaka, Japan), Kyorin Pharmaceutical Co. Ltd (Tokyo, Japan), Chugai-Seiyaku Co, Ltd (Tokyo, Japan) and Bristol-Myers Japan (Tokyo, Japan), respectively. RPMI 1640 medium (Gibe-BRL) and fetal bovine serum were purchased from Nisus (Tokyo, Japan).
MTT assay
The inhibitory effect of the drugs on the PC-14 cell line was determined using a colorimetric assay (MTT assay) according to the method of Mosmann. Figure 6 Heat map of correlations between drug profiles. Gene expression profiles containing data for 588 genes were compared after exposure to each drug to derive a matrix of Pearson correlation coefficients indicating the degree of overall similarity between any two drugs. A high-positive correlation is shown in red, and a low-positive correlation is shown in white. In this graph, TZT and D10 had the most similar expression profiles. TZT, TZT-1027; dolastatin 10, D10; VDS, vindesine; VCR, vincristine; VBL, vinblastine; TXL, paclitaxel; TXT, docetaxel.
Characterization of TZT-1027 in reference profiling T Shimoyama et al individual wells in a volume of 20 ml, and the cells were incubated for 72 h at 371C in humidified air containing 5% CO 2 . MTT reagents (MTT, Sigma) were then added to each well in a volume of 20 ml, and the cells were incubated for 4 h at 371C in humidified air containing 5% CO 2 . Finally, the growth inhibitory effect of each drug was assessed spectrophotometrically.
Drug treatment, RNA isolation and microarray hybridization To obtain reference profiles representing the drug-induced genomic response, the PC-14 cells were grown on plastic culture dishes until they reached 80% confluency; they were then treated with TZT-1027, D10, VDS, VCR, VBL, TXL and TXT for 6 h at the IC 50 concentration of each drug determined by MTT assay for 72 h. Cell pellets of the eight samples, including an untreated control, were collected by centrifugation, and the total RNA from each sample was isolated using a single-step guanidium thiocyanate procedure (ISOGEN; Nippon gene). 40 Single-channel labeling 32 P nylon membrane-based cDNA microarrays containing 588 genes were used (Atlas s Human Cancer cDNA Expression Array; BD Biosciences Clontech, Palo Alto, CA, USA). Protocols on array printing, labeling and hybridization are available at the BD Biosciences Clontech web site (http:// www.bdbiosciences.com/clontech/atlas/index.shtml) The hybridization intensities on X-ray films (Gel Bond s , FMC Bio Products Rockland, ME, USA) were scanned and quantified using a BAS-2000II scanner and Array Gauge software (Fuji Film, Tokyo).
Microarray data analysis
The intensity values of each gene were log-2-transformed and median-normalized using Excel software. The changes in gene expression induced by drug exposure were calculated for each spot by dividing the intensity of the drug exposure samples by that of the untreated samples. The multidimensional scaling analysis, based on a principle component analysis, was performed using SIMCA-P software v10.5 (Umetrics, Sweden). Three-dimensional rendering of the gene profiles was graphed in a manner such that samples with similar expression profiles would lie closer to each other than those with dissimilar profiles. The heat map, which showed the correlation coefficient between each drug reference profile, was performed by R (http://cran.r-project.org/).
Functional analysis of identified genes
To analyze the functions of the clustered genes, a gene ontology analysis was performed using the EASE bioinformatics software package (http://apps1.niaid. nih.gov/david/ upload.asp). 41, 42 This software package was used to rank functional clusters by statistical over-representation of individual genes in specific categories relative to all genes in the same category on the array. The functional clusters used by EASE were derived from the classification systems of Gene Ontology (GO). The P-value to rank categories of genes by over-representation was calculated using Jackknife-Fisher exact probabilities. The threshold for selecting categories was a P-value of less than 0.01 and a minimum gene count of more than two. P-values in gene ontology are not equal to biological significance but are helpful in focusing on the processes most likely to be associated with the biological phenomena associated with aging. We also conducted further online database searches to refine many specific GO annotations.
Real-time RT-PCR
Real-time RT-PCR was performed using a Smart Cycler system (Takara) and a SYBR Green PCR kit. The reaction solution was assembled in a volume of 25 ml comprised of TaqMant Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), forward and reverse primers (final concentration, 0.2 mmol/l each) and cDNA mixture (E2.5 ng) to produce PCR products specific for GSTP1 and TIMP3. The primers and probes were purchased from SigmaGenoSys (Tokyo, Japan). The conditions for real-time RT-PCR were preheating at 951C for 10 min, followed by 40 cycles of shuttle heating at 951C for 15 s and at 601C for 20 s. A threshold was set in the linear part of the amplification curve, and the number of cycles needed to reach it was calculated for every gene. Relative mRNA levels were determined using the included standard curves for each individual gene and further normalized to the GAPDH mRNA level. Melting curves were used to establish the purity of the amplified band. The sequences of the primers used for RT-PCR were as follows: GSTO1 forward, 5 0 -AGG TTC TGC CCG TTT GCT GAG AGG and reverse, 5 0 -CAA GCT TTC TCA TAG GGG TCA TCC G; TIMP3 forward, 5 0 -TGC TGA CAG GTC GCG TCT ATG ATG G and reverse, 5 0 -GCG TAG TGT TTG GAC TGG TAG CCA G; GAPDH forward, 5 0 -TGA AGG TCG GAG TCA ACG GAT TTG GT and reverse, 5 0 -CAT GTG GGC CAT GAG GTC CAC CAC.
